Kenvue Q2 Profit Beats Market, Sales Miss; Cuts FY25 Outlook

Kenvue (KVUE) reported mixed Q2 results, with adjusted EPS of $0.29 beating estimates but net sales falling 4.0% to $3.84 billion, missing expectations. More critically, the consumer health company significantly trimmed its fiscal 2025 outlook, now projecting adjusted EPS of $1.00-$1.05, well below the $1.13 consensus, and anticipating low-single-digit declines in net and organic sales, a sharp reversal from previous growth forecasts. This downgrade, attributed to a dynamic external environment, led to a modest pre-market share decline.

Analysis

Kenvue, Inc. (KVUE) has issued a significant downward revision to its fiscal 2025 guidance, which overshadows its mixed second-quarter financial results. While the company's Q2 adjusted earnings per share of $0.29 narrowly surpassed analyst estimates of $0.28, its net sales fell 4.0% year-over-year to $3.84 billion, missing the $3.85 billion consensus. The primary concern is the revised outlook for 2025, where projected adjusted EPS was cut to a range of $1.00-$1.05, substantially below the Wall Street consensus of $1.13 and a stark reversal from previous guidance for flat earnings. This new forecast incorporates a low-single-digit unfavorable impact from foreign currency. Furthermore, the company now anticipates a low-single-digit decline in both net and organic sales for the year, a material shift from its prior forecast of 1-3% and 2-4% growth, respectively. Management attributed the revision to a "dynamic external environment and underlying business fundamentals," signaling a deterioration in the company's core operational outlook.

Key Decisions for Investors

• The primary focus for investors should be the sharply reduced fiscal 2025 guidance, as the projected declines in sales and earnings signal deteriorating business fundamentals that override the minor Q2 earnings beat.
• Investors should re-evaluate valuation models for KVUE, as the new EPS guidance midpoint is approximately 11% below the prior consensus, suggesting that current price targets may be too optimistic.
• Monitor future management commentary for specific drivers behind the guidance cut, as the current explanation of a 'dynamic external environment' is vague and understanding the root causes is critical for assessing long-term prospects.
• The modest 0.5% pre-market share decline may not fully reflect the severity of the guidance revision, so investors should be cautious of potential further downside as the market digests the shift from expected growth to contraction.